" class="no-js "lang="en-US"> Whitelab Genomics - Pharmtech Focus
Tuesday, January 31, 2023
Whitelab Genomics | Pharmtech Focus

Whitelab Genomics

About Whitelab Genomics

Whitelab Genomics

WhiteLab Genomics, based in Paris and Cambridge (MA) was founded in 2019 by David Del Bourgo and Julien Cottineau, experts in genomics drug development and commercialization. WhiteLab Genomics aims to revolutionize genomic therapies development using public and private data and in-house AI algorithms. Whitelab Genomics supports its clients through the in-silico development phases enabling them to quickly develop target vectors and payloads and save precious time needed to give patients access to new genomic therapies. In only 2 years, Whitelab Genomics has convinced leading European and US Biotech and pharma to use its solutions for their new drug development programs, including RNA, DNA & Cell therapies. WhiteLab Genomics is also collaborating with world-renowned INSERM and Genethon laboratories and has been selected by Y-Combinator in its Winter 2022 batch. The company has won multiple awards, including the Galien Foundation nominee for startups, the Alumni New Venture Fund from the Polsky Innovation Center at the University of Chicago, and the Future 40 from Station F.

Related Story

Debiopharm Co-leads a 10M USD Series A Round to Accelerate the Development of Genomic Medicines through Artificial Intelligence

September 14 2022

Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm (www.Debiopharm.com), announced today […]